IRLAB: FDA meeting closing in - Redeye

Redeye updates its view of IRLAB following the Q4 report and largely reiterate our previous view. We think that the next significant trigger is the outcome of the end-of-phase II meeting on Mesdopetam, news on business development/financing and trial initiation of the IRL757 phase I trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/975208/irlab-q4-2023-fda-meeting-closing-in?utm_source=finwire&utm_medium=RSS